Genmab AS Quote - GMAB

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

26.65

Bid

26.64

Offer

26.66

Volume

109,072

26.31 Day's Range 26.66

0.00 52 Week Range 0.00

Market Cap

17.536B

Previous Close

26.54

Open

26.31

Last Trade

100

26.65

Last Trade Time

00:31:58

Financial Volume

US$ 2,893,968

VWAP

26.5326

Average Volume (3m)

Shares Outstanding

660,745,350

Dividend Yield

PE Ratio

40.62

Earnings Per Share (EPS)

6.59

Revenue

16.47B

Net Profit

4.35B

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biogenetic (human)

Website

www.genmab.com

Headquarters

Copenhagen, Dnk

Founded

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GMAB. The last closing price for Genmab AS was US$26.54. Over the last year, Genmab AS shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Genmab AS currently has 660,745,350 shares in issue. The market capitalisation of Genmab AS is US$17.54 billion. Genmab AS has a price to earnings ratio (PE ratio) of 40.62.

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all...

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC, presented in a rapid oral session at 2024...

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with...

Period †	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
1MCMorella Corporation Ltd	AUD 0.049 (1,533.33%)	158.83k
MSGMCS Services Limited	AUD 0.005 (400.00%)	26.31M
OSXOOsteopore Limited	AUD 0.007 (250.00%)	257.33k
DGRDGR Global Limited	AUD 0.03 (233.33%)	46.76M
LBTOALBT Innovations	AUD 0.009 (125.00%)	300k
VPRVolt Group Ltd	AUD 0.001 (-50.00%)	1.01M
1TTThrive Tribe Technologies Ltd	AUD 0.002 (-33.33%)	8.15M
ARVOCArtemis Resources Limited	AUD 0.002 (-33.33%)	4.92M
SIHSihayo Gold Limited	AUD 0.002 (-33.33%)	208k
SHOSportshero Limited	AUD 0.005 (-28.57%)	3.08M
DRODroneShield Limited	AUD 1.995 (-22.67%)	57.82M
NGSNutritional Growth Solutions Ltd	AUD 0.004 (33.33%)	54.75M
LSRLodestar Minerals Limited	AUD 0.001 (0.00%)	53.43M
DGRDGR Global Limited	AUD 0.03 (233.33%)	46.76M
OSXOsteopore Limited	AUD 0.065 (18.18%)	33.47M